Loading...
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
With the success of ipilimumab and promise of programmed death-1 pathway-targeted agents, the field of tumor immunotherapy is expanding rapidly. Newer targets for clinical development include select members of the tumor necrosis factor receptor (TNFR) family. Agonist antibodies to these co-stimulato...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
BioMed Central
2014
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4030310/ https://ncbi.nlm.nih.gov/pubmed/24855562 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2051-1426-2-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|